Advertisement
Advertisement
U.S. Markets open in 5 hrs 34 mins
Advertisement
Advertisement
Advertisement
Advertisement

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.76+0.10 (+0.68%)
At close: 04:00PM EST
14.76 0.00 (0.00%)
After hours: 05:39PM EST
Advertisement

Kezar Life Sciences, Inc.

4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 822 5600
http://www.kezarlifesciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees47

Key Executives

NameTitlePayExercisedYear Born
Mr. John Franklin FowlerCo-Founder, CEO & Director801.78kN/A1972
Dr. Christopher J. KirkCo-Founder, Pres, Chief Scientific Officer & Director590.16kN/A1972
Dr. Noreen Roth HenigChief Medical Officer616.17kN/A1965
Dr. Jack Taunton Ph.D.Co-FounderN/AN/AN/A
Mr. Marc L. BelskyCFO & Sec.N/AN/A1955
Michael WolfeDirector of Fin. & OperationsN/AN/AN/A
Ms. Vassiliki EconomidesSr. VP of Strategy & External AffairsN/AN/A1980
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.

Corporate Governance

Kezar Life Sciences, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement